10x Genomics, Inc. Earnings Recaps
10x Genomics reported third-quarter revenue of $151 million, up 1% year over year, with commercial shipments of Atera beginning. The stock rose 2.1% after earnings, a roughly flat reaction that suggests a measured response to the update.
Key takeaways
- Revenue was $151 million, up 1% year over year; management cited continued strength in consumables.
- Atera shipments have started. Management reported growing customer interest and said nearly all of the world’s top 20 biopharma companies had purchased Atera systems or Catalyst services.
- Catalyst Research Services attracted more than 100 customers booking projects in its first five months.
- Single Cell demand includes Flex Apex, whole-blood workflows and multimodal solutions; management said customers are also investing in automation to scale experiments.
The 9.6% stock jump reflects strong investor enthusiasm for the Atera platform, which drove robust order flow and broad customer engagement beyond initial expectations.
Key takeaways
- Q2 revenue was $151 million, including $1.6 million in non-recurring settlement revenue; organic revenue grew 3% year-over-year to $149 million.
- Atera launch generated unusually high early demand, with customers across academia and biopharma adopting the platform for diverse research applications including oncology and neurodegeneration.
- Strong growth in Chromium consumable reaction volumes and continued exceptional utilization of the Xenium spatial platform contributed to underlying strength.
- Catalyst Research Services, offering sample processing on Atera, has attracted strong interest as a flexible entry point for customers without immediate instrument access.
- Acquisition of Proteintech Genomics is expected to enhance Atera’s multi-omics capabilities, particularly in proteomics integration.
Shares declined 5% as investors reacted negatively to cautious commentary on growth momentum and the outlook, despite new product launches. The market appears disappointed by signs of deceleration and lack of clear near-term revenue upside from the recently introduced Atara platform.
Key takeaways
- Q1 revenue reached $151 million, up 9% year-over-year excluding a prior nonrecurring item.
- Single cell consumable volumes showed double-digit growth, driven by FLEX and FLEX Apex products.
- Spatial biology consumables also grew double digits, supported by Xenium; however, adoption remains early-stage.
- The new Atara instrument, touted as a major innovation enabling spatial whole transcriptome analysis at scale, is in early launch with promising initial feedback but no quantifiable contribution yet.
- Management emphasized the long-term potential of Atara but did not provide clear near-term guidance upside, suggesting cautious investor expectations on ramp and margins.
10X Genomics reported a solid third quarter, exceeding revenue expectations with $149 million driven by strong demand for both single-cell and spatial biology products despite ongoing macroeconomic challenges.
Key takeaways
- Total revenue of $149 million surpassed guidance, reflecting strong execution amid macro pressures.
- Significant year-over-year growth in spatial consumables, particularly for Xenium, continued to drive momentum.
- Expansion of product offerings, including new Chromium Flex and Xenium protein, is anticipated to enhance market adoption and streamline workflows.
- Ended the quarter with a robust $482 million cash position, ensuring flexibility for strategic investments.
- Customer sentiment indicates sustained cautious spending behavior, particularly concerning capital expenditures.